Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
SMC (468/08)
04/12/2024
Indication
Moderate to severe chronic plaque psoriasis in adult patients
Therapeutic Area
Skin
Status Description
Routinely available in line with national guidance
Formulation
-
Comments
Refer to pathway or local board guidelines for preferred formulation